{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001953926","name":"Zenas BioPharma, Inc.","summary":"Zenas BioPharma is a clinical-stage global biopharmaceutical company focused on immunology and inflammation (I&I). Its lead candidate, obexelimab, is a bifunctional monoclonal antibody targeting CD19 and FcRIIb for autoimmune diseases including IgG4-RD, RMS, and SLE. It also develops orelabrutinib (BTK inhibitor for progressive MS), ZB021 (oral IL-17 inhibitor), ZB022 (oral TYK2-JH2 inhibitor), and other early-stage I&I programs.","people":[],"products":[{"name":"Obexelimab","type":"platform","description":"Bifunctional monoclonal antibody targeting CD19 and FcRIIb to inhibit B cell activity in autoimmune diseases without B cell depletion."},{"name":"Orelabrutinib (ZB020)","type":"platform","description":"Highly selective, CNS-penetrant oral small molecule BTK inhibitor for progressive forms of multiple sclerosis."},{"name":"ZB021","type":"platform","description":"Oral small molecule IL-17AA/AF inhibitor blocking both IL-17AA homodimer and IL-17AF heterodimer signaling."},{"name":"ZB022","type":"platform","description":"Oral, brain-penetrant small molecule TYK2-JH2 inhibitor currently in IND-enabling studies."},{"name":"ZB002","type":"platform","description":"Anti-TNF monoclonal antibody designed with extended half-life compared to existing anti-TNF therapies."},{"name":"ZB004","type":"platform","description":"CTLA-4-Ig fusion protein designed with extended half-life compared to approved CTLA-4-Ig therapies."},{"name":"ZB001 (VRDN-001)","type":"platform","description":"IGF-1R monoclonal antibody sublicensed to Zai Lab for development and commercialization in greater China."},{"name":"ZB014","type":"platform","description":"Anti-CD19 and FcRIIb monoclonal antibody designed to extend half-life, currently in pre-clinical studies."}],"partnerships":[{"partner_name":"Bristol Myers Squibb & Co.","partnership_type":"licensing","description":"Holds exclusive development and commercialization rights for obexelimab in Japan, South Korea, Taiwan, Hong Kong, Singapore, and Australia.","start_date":null},{"partner_name":"InnoCare","partnership_type":"licensing","description":"Holds rights to obexelimab in certain InnoCare territories as noted in pipeline.","start_date":null},{"partner_name":"Zai Lab (Hong Kong) Limited","partnership_type":"licensing","description":"Granted exclusive sublicense to develop and commercialize ZB001 and related programs in greater China under January 2025 agreement.","start_date":null},{"partner_name":"Viridian Therapeutics, Inc.","partnership_type":"licensing","description":"Source of in-licensed development and commercialization rights for ZB001 (VRDN-001) in greater China.","start_date":null},{"partner_name":"Tenacia Biotechnology (Hong Kong) Co., Limited","partnership_type":"licensing","description":"Zenas transferred rights and obligations for ZB005 under agreements with Dianthus Therapeutics via October 2024 novation agreement.","start_date":null},{"partner_name":"Dianthus Therapeutics Inc.","partnership_type":"licensing","description":"Original counterparty to agreements for ZB005, rights subsequently transferred to Tenacia via novation.","start_date":null}],"affiliations":[],"origin":{"leaf":"5f0469e6af4b5e9e73979a8af59029f24712275a8119314bb0bb2b2881392631","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"e91cd85141acb37cd79fa25da4678e480c6ec577f1e7b7358a0d59f125e79c4a","parent":"59537d9d6a8c25a7bc7887ae2e2fa4324b1a8985b58d6234393c8911e8d6f527","source":"0001104659-26-027964","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":3,"hourly_limit":500,"remaining":497,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}